Application Nr Approved Date Route Status External Links
NDA212501 None Intravenous None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Cyclophosphamide Is An Alkylating Drug Indicated For Treatment Of: Malignant Diseases: Malignant Lymphomas: Hodgkin's Disease, Lymphocytic Lymphoma, Mixed-Cell Type Lymphoma, Histiocytic Lymphoma, Burkitt's Lymphoma; Multiple Myeloma, Leukemias, Mycosis Fungoides, Neuroblastoma, Adenocarcinoma Of Ovary, Retinoblastoma, Breast Carcinoma. ( 1.1 ) 1.1 Malignant Diseases Cyclophosphamide Is Indicated For The Treatment Of: Malignant Lymphomas (Stages Iii And Iv Of The Ann Arbor Staging System), Hodgkin's Disease, Lymphocytic Lymphoma (Nodular Or Diffuse), Mixed-Cell Type Lymphoma, Histiocytic Lymphoma, Burkitt's Lymphoma Multiple Myeloma Leukemias: Chronic Lymphocytic Leukemia, Chronic Granulocytic Leukemia (It Is Usually Ineffective In Acute Blastic Crisis), Acute Myelogenous And Monocytic Leukemia, Acute Lymphoblastic (Stem-Cell) Leukemia (Cyclophosphamide Given During Remission Is Effective In Prolonging Its Duration) Mycosis Fungoides (Advanced Disease) Neuroblastoma (Disseminated Disease) Adenocarcinoma Of The Ovary Retinoblastoma Carcinoma Of The Breast Cyclophosphamide, Although Effective Alone In Susceptible Malignancies, Is More Frequently Used Concurrently Or Sequentially With Other Antineoplastic Drugs.

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Cyclophosphamide Anhydrous

Comments